ContentsInnovationNew biopolymersFashion demands betterRegulation & policyTrump’s overhaulA new EU bioeconomy ...

In the last of our end-of-year pieces, business writers Coreena Ford and Tom Keighley pick their five companies to watch in ...

For most, the appeal is simple: convenience. Not everyone can grow a beard they like the look of. “When guys are so far ...

A detailed look at the UK business executives, entrepreneurs and industry innovators recognised in the 2026 New Year Honours ...

Biotech's 2025 rebound sets the stage for Denali Therapeutics and two peers, with key FDA decisions and pipeline catalysts ...

After meeting his father, on his way back, he stopped on the bridge over the Indrayani River in Takve Village. From there, he ...

A life-sciences job in Boston used to be a sure path to a high-paying career, but empty labs and unemployed grads now herald ...

Outlook Therapeutics faces a pivotal FDA decision for Lytenava on December 31st, following two prior rejections. Read why ...

The development came amid growing outrage over the Delhi high court’s recent decision to suspend Sengar’s life sentence ...

POLE STAR Krzysztof Ratajski kept his head as he produced an Ally Pally comeback – and then revealed he had BRAIN SURGERY ...

New PhD training programmes, delivered by Aberystwyth University with partner universities and industry, have been launched ...

The York-based Aptamer Group says it ends 2025 with strong momentum as global pharma partnerships drive confidence for 2026.